[1]
Benedict RH, Zivadinov R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol 2011; 7(6): 332-42.
[2]
Jakimovski D, Gandhi S, Paunkoski I, et al. Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: A 5-year longitudinal study. Eur J Neurol 2019; 26(1): 87-e8.
[3]
Thormann A, Magyari M, Koch-Henriksen N, Laursen B, Sørensen PS. Vascular comorbidities in multiple sclerosis: A nationwide study from Denmark. J Neurol 2016; 263(12): 2484-93.
[4]
Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol 2015; 15(9): 545-58.
[5]
Ziliotto N, Zivadinov R, Jakimovski D, et al. Plasma levels of soluble NCAM in multiple sclerosis. J Neurol Sci 2019; 396: 36-41.
[6]
Weinstock-Guttman B, Zivadinov R, Horakova D, et al. Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatry 2013; 84(11): 1186-91.
[7]
Jakimovski D, Topolski M, Genovese AV, Weinstock-Guttman B, Zivadinov R. Vascular aspects of multiple sclerosis: Emphasis on arterial and cardiovascular health. Expert Rev Neurother 2019. [Epub ahead of print].
[8]
Belov P, Jakimovski D, Krawiecki J, et al. Lower arterial cross-sectional area of carotid and vertebral arteries and higher frequency of secondary neck vessels are associated with multiple sclerosis. AJNR Am J Neuroradiol 2018; 39(1): 123-30.
[9]
Pelizzari L, Jakimovski D, Laganà MM, et al. Five-year longitudinal study of neck vessel cross-sectional area in multiple sclerosis. AJNR Am J Neuroradiol 2018; 39(9): 1703-9.
[10]
Jakimovski D, Topolski M, Kimura K, et al. Abnormal venous postural control: Multiple sclerosis-specific change related to gray matter pathology or age-related neurodegenerative phenomena? Clin Auton Res 2019; 29(3): 329-38.
[11]
Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69(2): 292-302.
[12]
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444-52.
[13]
Pelizzari L, Laganà MM, Jakimovski D, et al. Neck vessel cross-sectional area measured with MRI: Scan-rescan reproducibility for longitudinal evaluations. J Neuroimaging 2018; 28(1): 48-56.
[14]
Heil M, Eitenmüller I, Schmitz-Rixen T, Schaper W. Arteriogenesis versus angiogenesis: Similarities and differences. J Cell Mol Med 2006; 10(1): 45-55.
[15]
Heil M, Schaper W. Influence of mechanical, cellular, and molecular factors on collateral artery growth (arteriogenesis). Circ Res 2004; 95(5): 449-58.
[16]
Lassmann H. Pathology and disease mechanisms in different stages of multiple sclerosis. J Neurol Sci 2013; 333(1-2): 1-4.
[17]
la Sala A, Pontecorvo L, Agresta A, Rosano G, Stabile E. Regulation of collateral blood vessel development by the innate and adaptive immune system. Trends Mol Med 2012; 18(8): 494-501.
[18]
van Weel V, Toes RE, Seghers L, et al. Natural killer cells and CD4+ T-cells modulate collateral artery development. Arterioscler Thromb Vasc Biol 2007; 27(11): 2310-8.
[19]
Shalev I, Schmelzle M, Robson SC, Levy G. Making sense of regulatory T cell suppressive function. Semin Immunol 2011; 23(4): 282-92.
[20]
Stabile E, Kinnaird T, la Sala A, et al. CD8+ T lymphocytes regulate the arteriogenic response to ischemia by infiltrating the site of collateral vessel development and recruiting CD4+ mononuclear cells through the expression of interleukin-16. Circulation 2006; 113(1): 118-24.
[21]
Girolamo F, Errede M, Longo G, et al. Defining the role of NG2-expressing cells in experimental models of multiple sclerosis. A biofunctional analysis of the neurovascular unit in wild type and NG2 null mice. PLoS One 2019; 14(3): e0213508.
[22]
Absinta M, Nair G, Monaco MCG, Maric D, Lee NJ, Ha SK, et al. The “Central Vein Sign” in inflammatory demyelination: The role of fibrillar collagen type I. Ann Neurol 2019. [EPub ahead of Print].
[23]
Ziliotto N, Bernardi F, Jakimovski D, Zivadinov R. Coagulation pathways in neurological diseases: Multiple sclerosis. Front Neurol 2019. [EPub ahead of Print].
[24]
Schirmer SH, Fledderus JO, Bot PT, et al. Interferon-beta signaling is enhanced in patients with insufficient coronary collateral artery development and inhibits arteriogenesis in mice. Circ Res 2008; 102(10): 1286-94.
[25]
Schirmer SH, Bot PT, Fledderus JO, et al. Blocking interferon beta stimulates vascular smooth muscle cell proliferation and arteriogenesis. J Biol Chem 2010; 285(45): 34677-85.
[26]
Marshall O, Lu H, Brisset JC, et al. Impaired cerebrovascular reactivity in multiple sclerosis. JAMA Neurol 2014; 71(10): 1275-81.
[27]
Krogias C, Christou I, Tsivgoulis G, et al. Functional neurosonology reveals impaired cerebrovascular reactivity in multiple sclerosis. J Neuroimag 2019. [EPub ahead of Print]
[28]
Jakimovski D, Benedict RH, Marr K, et al. Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients. Mult Scler 2019. [Epub ahead of print].
[29]
Laganá MM, Mendozzi L, Pelizzari L, et al. Are cerebral perfusion and atrophy linked in multiple sclerosis? Evidence for a multifactorial approach to assess neurodegeneration. Curr Neurovasc Res 2018; 15(4): 282-91.
[30]
Power MC, Mormino E, Soldan A, et al. Combined neuropathological pathways account for age-related risk of dementia. Ann Neurol 2018; 84(1): 10-22.
[31]
Vaughn CB, Jakimovski D, Kavak KS, et al. Epidemiology and treatment of multiple sclerosis in elderly populations. Nat Rev Neurol 2019. [EPub ahead of Print].
[32]
Ferrucci L, Fabbri E. Inflammageing: Chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol 2018; 15(9): 505-22.
